Evidence map›Paper›PMID 31901302›Full record

ReviewTrends in endocrinology and metabolism: TEM2020

Melatonin Effects on Glucose Metabolism: Time To Unlock the Controversy.

Marta Garaulet, Jingyi Qian, Jose C Florez, Josephine Arendt, Richa Saxena, Frank A J L Scheer

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in endocrinology and metabolism: TEM, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Review

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marta GarauletDepartment of Physiology, University of Murcia and Research Biomedical Institute of Murcia, Murcia, Spain; Medical Chronobiology Program, Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Jingyi QianMedical Chronobiology Program, Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Jose C FlorezDepartment of Medicine, Harvard Medical School, Boston, MA, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Josephine ArendtUniversity of Surrey, Guildford, Surrey GU2 7XH, UK.
Richa SaxenaDepartment of Medicine, Harvard Medical School, Boston, MA, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. Electronic address: rsaxena@broadinstitute.org.
Frank A J L ScheerMedical Chronobiology Program, Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. Electronic address: fscheer@bwh.harvard.edu.

Funding

Genetics of chronotype and impact on metabolic diseaseR01DK107859 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Richa Saxena · 2016 to 2026
$4.0M
Melatonin and Receptor Gene Variant: Linking Circadian System and Type 2 DiabetesR01DK102696 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI SAXENA, RICHA, SCHEER, FRANK A · 2015 to 2019
$3.8M
Impact of Malatonin, Food Timing and Receptor Variant on Type 2 Diabetes RiskR01DK105072 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI SAXENA, RICHA, SCHEER, FRANK A · 2016 to 2020
$3.2M
NIDDK NIH HHS R01 DK102696NIDDK NIH HHS R01 DK105072NIDDK NIH HHS R01 DK107859
6 · The paper itself

Abstract

The past decade has witnessed a revival of interest in the hormone melatonin, partly attributable to the discovery that genetic variation in MTNR1B - the melatonin receptor gene - is a risk factor for impaired fasting glucose and type 2 diabetes (T2D). Despite intensive investigation, there is considerable confusion and seemingly conflicting data on the metabolic effects of melatonin and MTNR1B variation, and disagreement on whether melatonin is metabolically beneficial or deleterious, a crucial issue for melatonin agonist/antagonist drug development and dosing time. We provide a conceptual framework - anchored in the dimension of 'time' - to reconcile paradoxical findings in the literature. We propose that the relative timing between elevated melatonin concentrations and glycemic challenge should be considered to better understand the mechanisms and therapeutic opportunities of melatonin signaling in glycemic health and disease.

Indexed as

AnimalsBlood GlucoseCarbohydrate MetabolismCircadian RhythmDiabetes Mellitus, Type 2Genetic VariationGlucoseHumansInsulinMelatoninPolymorphism, Single NucleotideReceptor, Melatonin, MT2Blood GlucoseGlucoseInsulinMelatoninMTNR1B protein, humanReceptor, Melatonin, MT2circadian systemglucose metabolismmelatoninMTNR1Btype 2 diabetes

Identifiers

PMID31901302
PMCPMC7349733

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.